menu
    • menu
    [{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital T\u00fcbingen","sponsor":"Technische Universit\u00e4t Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | Universidade do Porto | Oslo University Hospital | Universit\u00e0 degli Studi di Udine ","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"University Hospital T\u00fcbingen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"University Hospital T\u00fcbingen \/ Technische Universit\u00e4t Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | Universidade do Porto | Oslo University Hospital | Universit\u00e0 degli Studi di Udine ","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital T\u00fcbingen \/ Technische Universit\u00e4t Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | Universidade do Porto | Oslo University Hospital | Universit\u00e0 degli Studi di Udine "},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | University of Oslo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"dr. M.J.N.L. Benders","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"dr. M.J.N.L. Benders","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"dr. M.J.N.L. Benders \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"dr. M.J.N.L. Benders \/ ZonMw"},{"orgOrder":0,"company":"Crystalys Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Dotinurad","moa":"||Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Crystalys Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Crystalys Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Crystalys Therapeutics \/ Novo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals for Allopurinol APS Brand

    Menu

    Allopurinol APS Brand

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crystalys Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Crystalys Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Novo-Backed Crystalys Debuts With $205M to Tackle Gout

                            Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.

                            Product Name : FYU-981

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2025

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Indoco Remedies Limited

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Indoco Remedies Limited

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indoco Remedies Gains USFDA Final Approval for Allopurinol Tablets USP 200 mg

                            Details : Zyloprim-Generic (allopurinol) is a xanthine oxidase inhibitor. It is indicated for the treatment of primary or secondary gout, leukemia, lymphoma and solid tumor malignancies.

                            Product Name : Zyloprim-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2025

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            dr. M.J.N.L. Benders

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            dr. M.J.N.L. Benders

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring ...

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2020

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Oslo University Hospital

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Oslo University Hospital

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : South-Eastern Norway Regional Health Authority | University of Oslo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lowering Uric Acid in Live Kidney Donors

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Living Donors / Kidney.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2017

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : South-Eastern Norway Regional Health Authority | University of Oslo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University Hospital Tübingen

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University Hospital Tübingen

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Technische Universität Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundación para la Investigación del Hospital Clínico de Valencia | Universidade do Porto | Oslo University Hospital | Università degli Studi di Udine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypoxia-Ischemia, Brain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2017

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Technische Universität Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundación para la Investigación del Hospital Clínico de Valencia | Universidade do Porto | Oslo University Hospital | Università degli Studi di Udine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IVIVR Assessing PK Parameters Used to Establish Bioequivalence

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2015

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ipca Laboratories

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ipca Laboratories

                            India arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2012

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2011

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allopurinol Outcome Study

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2011

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth